Oligon
1 known investors
Oligon Therapeutics develops RNA-based multi-targeting drugs using its SeekR platform, which combines RNA aptamer oligo-binders with siRNA silencers into a single self-delivering molecule for precise targeting of specific cell types, including T-cells and cancer cells. The biotechnology company applies AI-based molecular modeling to discover and optimize these RNA drug candidates.
Investors · 1
Frequently asked questions
- What does Oligon do?
- Oligon Therapeutics develops RNA-based multi-targeting drugs using its SeekR platform, which combines RNA aptamer oligo-binders with siRNA silencers into a single self-delivering molecule for precise targeting of specific cell types, including T-cells and cancer cells. The biotechnology company applies AI-based molecular modeling to discover and optimize these RNA drug candidates.
- Who are Oligon's investors?
- Oligon's investors include CTI Life Sciences Fund L.P..